Document Detail


Value of CRP in coronary risk determination.
MedLine Citation:
PMID:  19122252     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Initial studies showed that C-reactive protein (CRP) may have a role in the genesis of atherosclerotic lesions and as a novel biomarkers of patients at risk of developing coronary heart disease (CHD) events. Most of these studies had methodologic limitations, and recent data contradict these findings and suggest that inflammatory markers, such as CRP, have limited usefulness in the prediction of CHD events over and above conventional risk factors. Its low predictive value creates difficulty in interpreting the CRP data in an individual patient. Current scientific literature does not support measurement of CRP in individual patients in clinical medicine. In this review, we critically appraise role of CRP in cardiovascular medicine.
Authors:
Jawahar L Mehta; Rishi Sukhija; Francesco Romeo; Jorge L Sepulveda
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Indian heart journal     Volume:  59     ISSN:  0019-4832     ISO Abbreviation:  Indian Heart J     Publication Date:    2007 Mar-Apr
Date Detail:
Created Date:  2009-01-05     Completed Date:  2009-02-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0374675     Medline TA:  Indian Heart J     Country:  India    
Other Details:
Languages:  eng     Pagination:  173-7     Citation Subset:  IM    
Affiliation:
Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205-7199, USA. MehtaJL@uams.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Biological Markers
C-Reactive Protein / analysis*
Coronary Artery Disease / blood,  physiopathology*
Humans
Inflammation / blood,  physiopathology*
Prognosis
Risk Assessment
Risk Factors
Chemical
Reg. No./Substance:
0/Biological Markers; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cobalt chromium stent with antiproliferative for restenosis trial in India (COSTAR I).
Next Document:  [New development in bisphosphonate treatment. Fracture prevention by bisphosphonates].